HBV – Medxy AI

HBsAg <100 IU/mL Identifies Inactive Chronic HBV Patients with HCC Risk Below Surveillance Threshold

By MedXY 11/07/2025

A large Asian cohort study shows serum HBsAg <100 IU/mL reliably identifies inactive chronic hepatitis B patients whose annual HCC risk is <0.2%, potentially allowing de‑escalation of surveillance and informing partial HBV cure definitions.

Gastroenterology news Oncology

Unveiling the Molecular Link Between Alcohol and HBV-Driven Liver Cancer: The Role of ATF4/LPLA2-Mediated BMP Metabolism

By MedXY 10/28/2025

Chronic alcohol intake exacerbates HBV-induced hepatocellular carcinoma by activating the ATF4/LPLA2 pathway, promoting BMP metabolism and MAPK/ERK signaling, identifying LPLA2 as a potential therapeutic target and prognostic marker.

news Oncology

Alcohol’s Amplifying Effect on HBV-Related Liver Cancer: New Insights into Metabolic Reprogramming

By MedXY 10/27/2025

This article explores how alcohol consumption worsens HBV-induced hepatocellular carcinoma by promoting ER stress and lipid metabolic disturbances, highlighting potential therapeutic targets like LPLA2 and BMP.

Clinical Updates Infectious Diseases news

SCG101: A Novel HBV-Specific TCR-T Therapy Shows Promising Results in Advanced HBV-Related Hepatocellular Carcinoma

By MedXY 09/04/2025

SCG101, an HBV-specific T-cell receptor T-cell therapy, demonstrates significant antiviral and antitumour efficacy with a manageable safety profile in patients with advanced HBV-related hepatocellular carcinoma refractory to prior treatments.